600529.SHG Shandong Pharmaceutical Glass Co Ltd
- Market cap
- CNY 12.4B
- P/E
- 18.5x
- P/B
- 1.45x
- ROE
- 8.2%
- Dividend yield
- 2.99%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600529.SHG undervalued?
Graham number600529.SHG trades 9.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shandong Pharmaceutical Glass Co Ltd fundamental analysis
No fundamental analysis for Shandong Pharmaceutical Glass Co Ltd yet.
Shandong Pharmaceutical Glass Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shandong Pharmaceutical Glass Co Ltd
Shandong Pharmaceutical Glass Co.Ltd engages in research and development, production, and sale of various pharmaceutical glass packaging products in China. The company offers moulded glass products, including amber glass containers, dropper bottles, infusion bottles, cosmetic bottles, tablet bottle, food glass, cobalt blue and green bottles, and black bottles, as well as moulded glass injection vial comprising type I/II/III. It also provides tubular glass products, such as g…
Full company profileShandong Pharmaceutical Glass Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shandong Pharmaceutical Glass Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.06B | 2.33B | 2.58B | 2.99B | 3.43B | 3.88B | 4.19B | 4.98B | 5.13B | 4.47B | 4.33B |
| Gross Profit | 634M | 721M | 861M | 1.05B | 1.07B | 1.09B | 1.10B | 1.36B | 1.57B | 1.49B | 1.40B |
| Operating Income | 254M | 317M | 449M | 586M | 677M | 698M | 711M | 916M | 1.11B | 838M | 888M |
| EBITDA | 405M | 454M | 554M | 696M | 879M | 919M | 958M | 1.17B | 1.42B | 1.23B | 840M |
| Net Income | 190M | 263M | 358M | 459M | 564M | 591M | 618M | 776M | 943M | 690M | 694M |
| EPS | 0.38 | 0.44 | 0.60 | 0.77 | 0.95 | 0.99 | 1.03 | 1.17 | 1.42 | 1.04 | 1.05 |
| Balance Sheet | |||||||||||
| Total Assets | 3.90B | 4.18B | 4.62B | 5.17B | 5.62B | 6.41B | 8.78B | 9.32B | 10.1B | 10.0B | 10.1B |
| Total Liabilities | 861M | 930M | 1.10B | 1.30B | 1.37B | 1.74B | 1.82B | 1.78B | 2.13B | 1.75B | 1.56B |
| Shareholders' Equity | 3.04B | 3.25B | 3.53B | 3.87B | 4.26B | 4.67B | 6.96B | 7.53B | 8.01B | 8.29B | 8.50B |
| Cash & Short-term Investments | 1.08B | 714M | 834M | 1.52B | 1.36B | 1.19B | 2.45B | 2.68B | 2.79B | 2.75B | 1.01B |
| Total Debt | 1.00M | 381M | 417M | 432M | 490M | 714M | 5.20M | 1.83M | 750M | 23.4M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 507M | 412M | 466M | 599M | 566M | 750M | 252M | 1.05B | 1.17B | 577M | - |
| Capital Expenditure | 197M | 167M | 347M | 592M | 535M | 809M | 711M | 672M | 648M | 232M | 434M |
| Free Cash Flow | 310M | 245M | 118M | 7.36M | 30.8M | -58.8M | -458M | 376M | 517M | 345M | 384M |
| Ratios | |||||||||||
| ROE | 6.2% | 8.1% | 10.2% | 11.9% | 13.3% | 12.7% | 8.9% | 10.3% | 11.8% | 8.3% | 8.2% |
| ROA | 4.9% | 6.3% | 7.7% | 8.9% | 10.0% | 9.2% | 7.0% | 8.3% | 9.3% | 6.9% | 6.9% |
| Net Profit Margin | 9.2% | 11.3% | 13.9% | 15.3% | 16.5% | 15.3% | 14.8% | 15.6% | 18.4% | 15.4% | 16.0% |
| Debt to Equity | 0.00x | 0.12x | 0.12x | 0.11x | 0.12x | 0.15x | 0.00x | 0.00x | 0.09x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shandong Pharmaceutical Glass Co Ltd dividends
- Dividend yield
- 2.99%
- Forward dividend
- 0.60 CNY
- Payout ratio
- 53.7%
- Ex-dividend date
- Sep 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 370M | 0.56 | 53.7% |
| 2024 | CNY 465M | 0.70 | 49.3% |
| 2023 | CNY 199M | 0.30 | 25.7% |
| 2022 | CNY 178M | 0.30 | 28.9% |
| 2021 | CNY 178M | 0.30 | 30.2% |
| 2020 | CNY 178M | 0.30 | 31.6% |
| 2019 | CNY 127M | 0.21 | 27.8% |
| 2018 | CNY 101M | 0.17 | 28.1% |
| 2017 | CNY 57.0M | 0.10 | 21.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 20, 2019.
Who owns Shandong Pharmaceutical Glass Co Ltd
- Insiders 23.18%
- Institutions 6.60%
- Public & others 70.22%
- Shares outstanding 664M
- Free float 335M
Shandong Pharmaceutical Glass Co Ltd company profile
- Company name
- Shandong Pharmaceutical Glass Co Ltd
- Ticker
- 600529.SHG
- ISIN
- CNE000001BG9
- Exchange
- Shanghai Stock Exchange
- Listed since
- Jun 3, 2002
- Sector
- Consumer Cyclical
- Industry
- Health Care Equipment & Supplies
- Employees
- 6,775
- Fiscal year end
- December
- Address
- Yaobo Road, Zibo, China, 256100
- Phone
- 86 53 3325 9167
- Website
- pharmglass.com
About Shandong Pharmaceutical Glass Co Ltd
Shandong Pharmaceutical Glass Co.Ltd engages in research and development, production, and sale of various pharmaceutical glass packaging products in China. The company offers moulded glass products, including amber glass containers, dropper bottles, infusion bottles, cosmetic bottles, tablet bottle, food glass, cobalt blue and green bottles, and black bottles, as well as moulded glass injection vial comprising type I/II/III. It also provides tubular glass products, such as glass tubes for pharma use, other tubular bottle with screw neck finish, PFS and glass cartridges, tubular glass vials for injection, and ampoules. In addition, the company offers closures for glass containers comprising plastic bottles, dropper cap, plastic cap for bottles, plunger and combiseal for glass cartridge, teflon coated rubber stopper, rubber stopper for injection vial/bottle, accessories for PFS, and flip off cap and Al-seal. Further, it provides butyl rubber stopper for injection; and prefilled syringe, aluminum plastic multi-cap, plastic dropper cap, dropper, caps for dropper bottle, and white HDPE bottles. The company also exports its products to to Europe, the United States, Russia, Japan, Korea, Southeast Asia, and internationally. Shandong Pharmaceutical Glass Co.Ltd was founded in 1970 and is based in Zibo, China.
Shandong Pharmaceutical Glass Co Ltd management
9- Mr. Jun ZhangGM & Director · born 1969
- Mr. Yizhao SongDeputy GM & CFO · born 1974
- Mr. Gang ChenExecutive Deputy GM & Director · born 1977
- Mr. Xingjun WangDeputy GM & Director · born 1972
- Mr. Haibao ZhaoSecretary of the Board of Directors · born 1968
- Mr. Wansheng HeDeputy General Manager · born 1977
- Mr. Yucai SuDeputy General Manager · born 1969
- Mr. Bin DuDeputy General Manager · born 1973
- Mianxing LiuAccounting Supervisor